Comparison of diagnostics power of chromogranin Aelisa test in general population of patients with neuroendocrine tumors and with metastases
DOI:
https://doi.org/10.12923/Keywords:
diagnostic power of CgA Elisa test, neuroendocrine tumoursAbstract
Neuroendocrine tumours (NET) are a rare and heterogeneous group of neoplasms derived from neuroendocrine cells scattered in the body. These cells mainly produce numerous peptides and biogenic amines i.e. chromogranin A. Despite many limitations CgA has been successfully used in the diagnosis of NET. It is a well-recognized marker for treatment monitoring and prognosis of disease course for patients diagnosed with NET. The purpose of this study was to evaluate the diagnostic usefulness of CgA Elisa test in the group of patients with NET and in selected groups of patients with metastases. The evaluation was performed in the group of 70 patients diagnosed with NET and 52 (74%) of them had confirmed metastases, 18 (26%) had no metastases detected. In order to investigate the diagnostic usefulness of serum CgA we plotted ROC curves (Receiver Operating Characteristic) and area under the curve (AUC) was calculated. Sensitivity, specificity, positive and negative predictive values were calculated using the standard equations for CgA cut-off set at 19 U/l obtaining values of 67%, 85%, 89%, 55% respectively. We also evaluated diagnostics power of CgA evaluation in selected groups of patients: with metastases to the liver and/or bone, lung, brain, lymph nodes. Diagnostics sensitivity of CgA in this group was 89%, however in the group of patients with metastases to the lymph nodes and distant organs reached the level of 75%. We conclude that the ELISA test from DacoCytomation for the determination of chromogranin A in serum used in this study has a good diagnostic power in detecting neuroendocrine tumors.
References
1. Akobeng A.K.: Understanding diagnostics tests 1: sensitivity, specificity and predictive values. Acta Paediatr. 96, 338, 2007.
2. Bajetta E., Ferrari L., Martinetti A. et al: Chromogranin A, neuron-specific enolase, carcinoembryonic antigen and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer, 86, 858, 1999.
3. Baudin E., Bidart J.M., Bachelot A. et al: Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann. Oncol. 12, 79, 2001.
4. Będkowska G.E., Ławicki S., Szmitkowski M.: Markery nowotworowe przydatne w diagnostyce i monitorowaniu raka endometrium i szyjki macicy. Postepy Hig. Med. Dosw. 61, 122, 2007.
5. Bolanowski M.: Wybrane aspekty kliniczne guzów neuroendokrynnych. Fam. Med. Prim. Care Rev. 10, 788, 2008.
6. Campana D., Nori F., Piscitelli L. et al: Chromogranin A: Is It a Useful Marker of neuroendocrine Tumors?. J. Clin. Oncol. 25, 1967, 2007.
7. Caplin M.E., Wiedenmann B.: The management of patients with neuroendocrine tumors. Endoc. Relat. Cancer, 10, 425, 2003.
8. Cotter K., Peipert J.F.: Can you handle the truth (and know it when you see it)? Understanding sensitivity, specificity and predictive values, and ROC curves. J. Minim. Invasive Gynecol. 12, 385, 2005.
9. Ćwikła J.B., Nasierowska-Guttmejer A., Jeziorski K.G. et al: Diagnostic algorithm of neuroendocrine tumors of the digestive system (GEP-NET) and bronchi. Pol. J. Radiol. 70, 87, 2005.
10. Dziarkowska K., Wieczorek P.: Nowotwory tarczycy-klasyczne techniki diagnostyczne i markery nowotworowe. Kosmos, 55, 267, 2006.
11. Giovanella L.: Chromogranin A a circulating neuroendocrine marker. Cis. Bio. 1, 2003.
12. Glinicki P., Jeske W.: Chromogranina A (CgA) — charakterystyka dostępnych metod badawczych i uwarunkowań mogących mieć wpływ na uzyskane wyniki. Endokrynol. Pol. 60, 415, 2009.
13. Janson E.T., Holmberg L., Stridsberg M. et al: Carcinoid tumors: analysis of prognostic factors and survival in 301 patients. Ann. Oncol. 8, 685, 1997.
14. Kaltas G.A., Besser G.M., Grossman A.B.: The diagnosis and medical management of advanced neuroendocrine tumors. Endocr. Rev. 25, 458, 2004.
15. Kos-Kudła B.: Guzy neuroendokrynne przewodu pokarmowego. Onkologia po Dyplomie, 5, 2005.
16. Kulpa J., Rychlik U.: Markery nowotworowe w diagnostyce laboratoryjnej cz. I.
Bad. Diagn. 10, 9, 2004.
17. Nehar D., Lombard-Bohas C., Olivieri S. et al: Interest of Chromogranin A for diagnosis and follow-up of endocrine tumours. Clin. Endocrinol. 60, 644, 2004.
18. Nobels F.R.E., Kwekkeboom D.J., Bouillon R. et al: Chromogranin A: its clinical value as marker of neuroendocrine tumours. Eur. J. Clin. Invest. 24, 431, 1998.
19. Peracchi M., Conte D., Gebbia C. et al: Plasma chromogranin A in patients with sporadic gastro-entero-pancreatic neuroendocrine tumours or multiple endocrine neoplasia type 1. Eur. J. Endocrinol. 148, 39, 2003.
20. Seregni E., Ferrari L., Bajetta E., et. al: Clinical significance of blood chromogranin A measurement in neuroendocrine tumours. Ann. Oncol. 12, S69, 2001.
21. Soborczyk A., Deptała A.: Markery nowotworowe w praktyce klinicznej. Chor. Serca Naczyń, 4, 184, 2007.
22. Stivanello M., Berruti A., Torta M. et al: Circulating chromogranin A in the assessment of patients with neuroendocrine tumours. A single institution experience. Ann. Oncol. 12, 573, 2001.
23. Stridsberg M., Eriksson B., Oberg K. et al: A comparison between three commercial kits for chromogranin A measurements. J. Endocrinol. 177, 337, 2003.
24. Taupenot L., Harper K.L., O’Connor D.T.: The Chromogranin – Secretogranin Family. N. Engl. J. Med. 348, 1134, 2003.
25. Tomassetti P., Miglior M., Simoni P. et al: Diagnostic value of plasma chromogranin A in neuroendocrine tumours. Eur. J. Gastroenterol. Hepatol. 13, 55, 2001.
26. Vinik A.: Carcinoid tumors. Diffuse Hormonal System. Endotext.com 2004.
27. Zatelli M.C., Torta M., Leon A. et al: Chromogranin A as a marker of neuroendonecrine neoplasia: an Italaian Multicenter study. Endocr. Relat. Cancer, 14, 473, 2007.
Downloads
Published
Issue
Section
License
Copyright (c) 2011 Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
